With the election in the rear-view—and Inauguration Day just a few weeks off—plenty of investors have asked me what they should do with their portfolios now.
I’ll name five bargain dividend growers that should be on your buy list in a moment. But first, here are 2 sectors—and 9 stocks—you need to handle with care.
Let These 4 Growth Rockets Cool Down
On October 3, I pounded the table on defense stocks, namely Raytheon (RTN) and Northrop Grumman (NOC), and infrastructure plays Cummins (CMI) and Parker Hannifin (PH).
I hope you followed that advice, because all four have beaten the SPDR S&P 500 ETF (SPY) since then.
If you missed out, I’m afraid you’re too late. Even though all four companies are great long-term holds, President-elect Trump’s infrastructure and defense plans (or at least what we know of them) look baked in, with RTN, NOC, CMI and PH all boasting price-to-earnings (P/E) near fiv e-year highs.
Top Dividend Stocks To Invest In Right Now: Ormat Technologies, Inc.(ORA)
- [By Peter Graham]
A long term performance chart shows shares of U.S. Geothermal back in positive territory while potential peer mid cap Calpine Corporation (NYSE: CPN) is underperforming and Ormat Technologies, Inc (NYSE: ORA) has been taking off for two years:
Top Dividend Stocks To Invest In Right Now: Ryder System Inc.(R)
- [By Ben Levisohn]
Ryder System (R) tumbled to the bottom of the S&P 500 today after it missed earnings forecasts and cut its full-year guidance.
Ryder Systemdropped 14% to $68.28 today, while the S&P 500 0.6% to 2,388.61
Ryder Systems reported a profit of 82 cents a share, missing forecasts for 84 cents, on sales of $1.75 billion, ahead of forecasts for $1.7 billion. Ryder cut its 2017 guidance to a range of $4.25 to $4.55, below the Street consensus for $5.17.
Ryder System’s market capitalization fell to $3.7 billion today from $4.2 billion yesterday.
Top Dividend Stocks To Invest In Right Now: Aurinia Pharmaceuticals Inc(AUPH)
- [By Lisa Levin] Related NVCN 18 Biggest Mid-Day Losers For Wednesday Legal Overhangs Keep Ladenburg Neutral On Neovasc Despite Positive Tiara Clinical Data Boston Scientific closes Neovasc transaction (Seeking Alpha) Related BSX Watch These 10 Huge Call Purchases In Monday Trade Wonderful Wearables Get Their Own ETF Boston Scientific closes Neovasc transaction (Seeking Alpha) Gainers Neovasc Inc (US) (NASDAQ: NVCN) rose 17.3 percent to $2.65 in pre-market trading after the company reported the close of its $75 million transaction with Boston Scientific Corporation (NYSE: BSX). aTyr Pharma Inc (NASDAQ: LIFE) shares rose 12.3 percent to $4.10 in pre-market trading after the company disclosed 'promising' signals in myopathies with Resolaris in exploratory trials. Globus Maritime Ltd (NASDAQ: GLBS) shares rose 10.1 percent to $6.90 in pre-market trading after climbing 5.03 percent on Monday. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares rose 9.9 percent to $3.00 in pre-market trading. Aurinia Pharmaceuticals appointed Lorin Jeffry “Jeff” Randall to its board and Chairman of the Audit Committee. Ocean Rig UDW Inc. (NASDAQ: ORIG) shares rose 8.7 percent to $2.89 in pre-market trading after surging 19.82 percent on Monday. Full House Resorts, Inc. (NASDAQ: FLL) shares rose 5.1 percent to $2.08 in pre-market trading after declining 1.98 percent on Monday. Seadrill Ltd (NYSE: SDRL) rose 5.1 percent to $4.13 in pre-market trading after surging 3.15 percent on Monday. Noble Corporation (NYSE: NE) rose 5.1 percent to $7.60 in pre-market trading after declining 5.37 percent on Monday. Arbutus Biopharma Corp (NASDAQ: ABUS) rose 5.1 percent to $3.10 in pre-market trading. Arbutus issued additional data from its ARB-1467 Phase II
- [By Lisa Levin]
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares shot up 24 percent to $4.60 after the company disclosed that Voclosporin met 48-week remission endpoints.
- [By Todd Campbell]
After positive mid-stage trial data suggested earlier this year that it might be able to reshape the treatment of kidney failure in lupus patients, Aurinia Pharmaceuticals (NASDAQ:AUPH)has announced plans for a late-stage study that could eventually allow it to win regulatory OKs in the U.S., Europe, and Japan.